Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1106-1112

  Valtorta, Silvia ^a,b   Belloli, Sara ^a,b   Sanvito, Francesca ^b   Masiello, Valeria ^a,b   Di Grigoli, Giuseppe ^a,b   Monterisi, Cristina ^a,b   Fazio, Ferruccio ^a,b   Picchio, Maria ^a,b   Moresco, Rosa Maria ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

18F FAZA; 64Cu ATSM; PET imaging; Tumor hypoxia

Indexed keywords

CARBONATE DEHYDRATASE IX; COPPER EXPORTING ADENOSINE TRIPHOSPHATASE; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) C 64; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BREAST CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; EX VIVO STUDY; FEMALE; GOLD STANDARD; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOLOCALIZATION; IN VIVO STUDY; MALE; MOUSE; NEOPLASM; NONHUMAN; PHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOACTIVITY; TUMOR HYPOXIA; TUMOR XENOGRAFT; 18F-FAZA; 64CU-ATSM; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; PET IMAGING; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

18F-FAZA; 64CU-ATSM; PET IMAGING; TUMOR HYPOXIA;

ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THIOSEMICARBAZONES; TISSUE DISTRIBUTION;

EID: 84879990817     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111120     Document Type: Article

References (40)

1. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14:191-201.
2. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207-214.
3. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26:241-248.
4. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225-239.
5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
6. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(suppl 5):4-9.
7. Tafani M, Di Vito M, Frati A, et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflammation. 2011;8:32-47.
8. Wang Y, Liu Y, Malek SN, Zheng P. Targeting HIF1a eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8:399-411.
9. Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 2012;109:2784-2789.
10. Chapman JD. Hypoxic sensitizers: implications for radiation therapy. N Engl J Med. 1979;301:1429-1432.
11. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106-113.
12. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623-630.
13. Souvatzoglou M, Grosu AL, Roper B, et al. Tumour hypoxia imaging with [18F] FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566-1575.
14. Reischl G, Dorow DS, Cullinane C, et al. Imaging of tumor hypoxia with [124I] IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results. J Pharm Pharm Sci. 2007;10:203-211.
15. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
16. Minagawa Y, Shizukuishi K, Koike I, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med. 2011;25:339-345.
17. Grigsby PW, Malyapa RS, Higashikubo R, et al. Comparison of molecular markers of hypoxia and imaging with 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol. 2007;9:278-283.
18. Yoshii Y, Furukawa T, Kiyono Y, et al. Internal radiotherapy with copper-64- diacetyl-bis (N4-methylthiosemicarbazone) reduces CD1331 highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38:151-157.
19. Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res. 2003;63:5496-5504.
20. O'Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493-1502.
21. Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and smallanimal PET comparisons between 18F-FMISO, 18F-FDG, 18F-FLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713-720.
22. Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37:237-243.
23. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999; 40:177-183.
24. McQuade P, Martin KE, Castle TC, et al. Investigation into 64Cu-labeled Bis (selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol. 2005;32:147-156.
25. Donnelly PS, Liddell JR, Lim S, et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis (4-methylthiosemicarbazonato)copperII. Proc Natl Acad Sci USA. 2012;109: 47-52.
26. Reischl G, Ehrlichmann W, Bieg C, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot. 2005;62:897-901.
27. Cottone L, Valtorta S, Capobianco A, et al. Evaluation of the role of tumorassociated macrophages in an experimental model of peritoneal carcinomatosis using 18F-FDG PET. J Nucl Med. 2011;52:1770-1777.
28. Matarrese M, Bedeschi P, Scardaoni R, et al. Automated production of copper radioisotopes and preparation of high specific activity [64Cu]Cu-ATSM for PET studies. Appl Radiat Isot. 2010;68:5-13.
29. Ilie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with nonsmall cell lung cancer. Br J Cancer. 2010;102:1627-1635.
30. Trastour C, Benizri E, Ettore F, et al. HIF-1a and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007;120:1451-1458.
31. Xiao ZY, Tang H, Xu ZM, et al. An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biol Ther. 2011;11:974-980.
32. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420-1431.
33. Holland JP, Giansiracusa JH, Bell SG, Wong LL, Dilworth Jr. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol. 2009;54:2103-2119.
34. Wessling-Resnick M. Understanding copper uptake at the molecular level. Nutr Rev. 2002;60:177-179.
35. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol. 2003;64:466-473.
36. Martinez-Balibrea E, Martinez-Cardus A, Musulen E, et al. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer. 2009;124: 2905-2910.
37. Turski ML, Brady DC, Kim HJ, et al. A novel role for copper in Ras/mitogenactivated protein kinase signaling. Mol Cell Biol. 2012;32:1284-1295.
38. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med. 2001;15:293-296.
39. Yoshii Y, Yoneda M, Ikawa M, et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less r0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol. 2012;39:177-185.
40. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118: 3930-3942.